Lv5
1330 积分 2023-11-16 加入
Advances in structural-guided modifications of siRNA
2天前
已完结
LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION
15天前
已关闭
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD
15天前
已完结
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition
17天前
已关闭
Estimation of the major cardiovascular events prevention with Inclisiran
17天前
已完结
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
17天前
已完结
Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
17天前
已完结
A Receptor-Mediated Pathway for Cholesterol Homeostasis
17天前
已完结
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
18天前
已完结
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
18天前
已完结
皖公网安备34019202002308
